Vertex Pharmaceuticals (1VRTX) Ratios
Vertex Pharmaceuticals Ratios
IT:1VRTX's free cash flow for Q2 2026 was $1.01B. For the 2026 fiscal year, IT:1VRTX's free cash flow was decreased by $-112.20M and operating cash flow was $1.13B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.90 | 2.69 | 3.99 | 4.83 | 4.46 |
| Quick Ratio | 2.46 | 2.35 | 3.78 | 4.66 | 4.30 |
| Cash Ratio | 1.32 | 1.28 | 2.92 | 3.83 | 3.17 |
| Solvency Ratio | 0.56 | -0.05 | 0.74 | 0.82 | 0.74 |
| Operating Cash Flow Ratio | 0.94 | -0.14 | 1.00 | 1.51 | 1.23 |
| Short-Term Operating Cash Flow Coverage | 43.86 | -5.34 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 3.72B | $ 3.47B | $ 8.99B | $ 9.00B | $ 6.23B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.08 | 0.04 | 0.05 | 0.07 |
| Debt-to-Equity Ratio | 0.21 | 0.11 | 0.05 | 0.06 | 0.10 |
| Debt-to-Capital Ratio | 0.17 | 0.10 | 0.04 | 0.06 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.37 | 1.29 | 1.30 | 1.33 |
| Debt Service Coverage Ratio | 43.46 | -2.42 | 87.19 | 64.33 | 41.13 |
| Interest Coverage Ratio | 357.95 | -7.61 | 86.89 | 78.60 | 45.24 |
| Debt to Market Cap | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 15.24 | 6.91 | 3.31 | 3.73 | 3.99 |
| Net Debt to EBITDA | -0.25 | -5.80 | -2.08 | -2.17 | -2.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 85.03% | 86.11% | 87.21% | 87.90% | 88.06% |
| EBIT Margin | 38.56% | 2.53% | 44.83% | 48.01% | 36.86% |
| EBITDA Margin | 40.30% | 4.41% | 46.66% | 49.67% | 38.52% |
| Operating Profit Margin | 39.43% | -2.11% | 38.83% | 48.23% | 36.73% |
| Pretax Profit Margin | 38.45% | 2.25% | 44.38% | 47.39% | 36.05% |
| Net Profit Margin | 32.74% | -4.86% | 36.68% | 37.20% | 30.92% |
| Continuous Operations Profit Margin | 32.74% | -4.86% | 36.68% | 37.20% | 30.92% |
| Net Income Per EBT | 85.14% | -215.53% | 82.64% | 78.49% | 85.78% |
| EBT Per EBIT | 97.53% | -106.70% | 114.30% | 98.26% | 98.14% |
| Return on Assets (ROA) | 15.12% | -2.38% | 15.92% | 18.30% | 17.44% |
| Return on Equity (ROE) | 21.18% | -3.26% | 20.59% | 23.88% | 23.19% |
| Return on Capital Employed (ROCE) | 21.37% | -1.23% | 19.98% | 27.95% | 24.64% |
| Return on Invested Capital (ROIC) | 18.12% | 2.63% | 16.44% | 21.81% | 20.99% |
| Return on Tangible Assets | 16.05% | -2.60% | 17.40% | 20.18% | 19.47% |
| Earnings Yield | 3.41% | -0.52% | 3.45% | 4.49% | 4.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.88 | 6.85 | 6.31 | 6.19 | 6.66 |
| Payables Turnover | 3.91 | 3.71 | 3.46 | 3.55 | 4.64 |
| Inventory Turnover | 1.07 | 1.27 | 1.71 | 2.35 | 2.56 |
| Fixed Asset Turnover | 3.92 | 4.26 | 6.79 | 6.13 | 5.32 |
| Asset Turnover | 0.46 | 0.49 | 0.43 | 0.49 | 0.56 |
| Working Capital Turnover Ratio | 1.81 | 1.33 | 0.94 | 1.00 | 1.11 |
| Cash Conversion Cycle | 309.50 | 242.28 | 165.94 | 111.89 | 118.60 |
| Days of Sales Outstanding | 62.05 | 53.31 | 57.82 | 58.94 | 54.78 |
| Days of Inventory Outstanding | 340.70 | 287.47 | 213.64 | 155.62 | 142.54 |
| Days of Payables Outstanding | 93.25 | 98.49 | 105.52 | 102.68 | 78.72 |
| Operating Cycle | 402.76 | 340.77 | 271.46 | 214.57 | 197.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 14.20 | -1.91 | 13.73 | 16.13 | 10.26 |
| Free Cash Flow Per Share | 12.49 | -3.07 | 12.72 | 15.33 | 9.35 |
| Dividend Paid and CapEx Coverage Ratio | 8.30 | -1.65 | 13.69 | 20.18 | 11.25 |
| Capital Expenditure Coverage Ratio | 8.30 | -1.65 | 13.69 | 20.18 | 11.25 |
| Operating Cash Flow Coverage Ratio | 0.94 | -0.28 | 4.38 | 4.59 | 2.73 |
| Operating Cash Flow to Sales Ratio | 0.30 | -0.04 | 0.36 | 0.46 | 0.35 |
| Free Cash Flow Yield | 2.76% | -0.76% | 3.13% | 5.31% | 4.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 29.32 | -193.61 | 28.97 | 22.26 | 24.16 |
| Price-to-Sales (P/S) Ratio | 9.60 | 9.41 | 10.62 | 8.28 | 7.47 |
| Price-to-Book (P/B) Ratio | 6.21 | 6.32 | 5.96 | 5.32 | 5.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 36.30 | -131.21 | 31.98 | 18.84 | 23.50 |
| Price-to-Operating Cash Flow Ratio | 31.92 | -210.51 | 29.64 | 17.91 | 21.41 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 1.69 | 3.48 | 0.52 | -1.87 |
| Enterprise Value Multiple | 23.57 | 207.43 | 20.69 | 14.51 | 17.40 |
| Enterprise Value | 114.72B | 100.88B | 95.29B | 64.35B | 50.76B |
| EV to EBITDA | 23.57 | 207.43 | 20.69 | 14.51 | 17.40 |
| EV to Sales | 9.50 | 9.15 | 9.66 | 7.21 | 6.70 |
| EV to Free Cash Flow | 35.92 | -127.64 | 29.06 | 16.39 | 21.08 |
| EV to Operating Cash Flow | 31.59 | -204.78 | 26.94 | 15.58 | 19.20 |
| Tangible Book Value Per Share | 67.08 | 56.29 | 60.74 | 47.72 | 33.75 |
| Shareholders’ Equity Per Share | 73.00 | 63.73 | 68.22 | 54.33 | 39.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 3.16 | 0.17 | 0.22 | 0.14 |
| Revenue Per Share | 47.22 | 42.80 | 38.30 | 34.87 | 29.39 |
| Net Income Per Share | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 |
| Tax Burden | 0.85 | -2.16 | 0.83 | 0.78 | 0.86 |
| Interest Burden | 1.00 | 0.89 | 0.99 | 0.99 | 0.98 |
| Research & Development to Revenue | 0.31 | 0.33 | 0.32 | 0.30 | 0.40 |
| SG&A to Revenue | 0.15 | 0.13 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
| Income Quality | 0.92 | 0.92 | 0.98 | 1.24 | 1.13 |
Currency in USD